<DOC>
	<DOCNO>NCT00066690</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast tumor cell . Ovarian function suppression combine hormone therapy use tamoxifen exemestane may fight breast cancer reduce production estrogen . It yet know whether suppression ovarian function plus either tamoxifen exemestane effective tamoxifen alone prevent recurrence hormone-responsive breast cancer . PURPOSE : This randomized phase III trial study ovarian suppression either tamoxifen exemestane see well work compare tamoxifen alone treat premenopausal woman undergone surgery hormone-responsive breast cancer .</brief_summary>
	<brief_title>Suppression Ovarian Function With Either Tamoxifen Exemestane Compared With Tamoxifen Alone Treating Premenopausal Women With Hormone-Responsive Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare disease-free survival , breast cancer-free interval , distant recurrence-free interval overall survival premenopausal woman endocrine-responsive breast cancer treat tamoxifen + ovarian function suppression ( triptorelin , oophorectomy , ovarian irradiation ) exemestane + ovarian function suppression vs. tamoxifen alone . The primary comparison ovarian function suppression either tamoxifen exemestane vs. tamoxifen alone . - Compare quality life , include late side effect early menopause , patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , prior adjuvant/neoadjuvant chemotherapy ( yes v ) , number positive axillary and/or internal mammary lymph node ( 0 vs 1 ) intend initial method ovarian function suppression ( triptorelin v oophorectomy v ovarian irradiation ) . Treatment duration 5 year . Patients follow every 3 month 1 year , every 6 month 5 year , annually thereafter . Quality life assess baseline , every 6 month 2 year , annually 4 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Premenopausal woman ( estradiol [ E2 ] premenopausal range [ accord institution parameter ] ) meet follow criterion : Patients receive chemotherapy randomize within 12 week definitive surgery ; patient estradiol ( E2 ) premenopausal range follow surgery ; patient require test estradiol ( E2 ) confirm premenopausal status menstruate regularly 6 month prior randomization use form hormonal contraception hormonal treatment 6 month prior randomization Patients receive prior adjuvant and/or neoadjuvant chemotherapy randomize complete chemotherapy within 8 month final dose chemotherapy soon premenopausal status confirm ; patient premenopausal status confirm estradiol ( E2 ) premenopausal range 2 week 8 month complete chemotherapy Adjuvant trastuzumab ( Herceptin Â® ) allowable , consider chemotherapy eligibility time determination Patients temporary chemotherapyinduced amenorrhea regain premenopausal status within eight month final dose chemotherapy eligible ; ( please note patient take tamoxifen aromatase inhibitor , even without evidence menses , may ovarian function recovery follow chemotherapy resume estradiol secretion ) ; patient wish participate study , postmenopausal hormone level shortly chemotherapy , recommend recheck estradiol level later timepoint within 8 month complete chemotherapy , even absence return menses Histologically proven , resect breast cancer ; pathology material available submission central review part quality control measure protocol Patients must hormone receptor positive tumor ; one breast tumor , tumor must hormone receptor positive ; hormone receptor must determine use immunohistochemistry ; estrogen receptor ( ER ) and/or progesterone receptor ( PgR ) must great equal 10 % tumor cell positive immunohistochemical evaluation ; biochemical determination alone acceptable The tumor must confine breast axillary node without detected metastasis elsewhere , exception tumor detect internal mammary chain node sentinel node procedure ; patient receive neoadjuvant therapy must operable disease prior neoadjuvant treatment eligible ; patient pathological evaluation tru cut core biopsy invasive breast cancer prior neoadjuvant therapy find invasive tumor pathological specimen definitive surgery eligible ; patient , preneoadjuvant tumor characteristic use define eligibility ; case persistent disease , pathology finding definitive surgery use Patients must proper surgery primary breast cancer know clinical residual locoregional disease : A total mastectomy ; radiotherapy optional mastectomy OR A breastconserving procedure ( lumpectomy , quadrantectomy partial mastectomy margin clear invasive cancer ductal breast carcinoma situ [ DCIS ] ) ; local pathologist must document negative margin resection pathology report ; margin clear , positive posterior ( deep ) margin permit , provide surgeon document excision perform pectoral fascia tumor remove ; likewise , margin clear , positive anterior ( superficial ; abut skin ) margin permit provided surgeon document tumor remove ; radiation therapy conserve breast require ; patient may randomize , completion radiation therapy breast Either axillary lymph node dissection ( pathological examination least 6 node recommend ) negative axillary sentinel node biopsy ( pN0 [ sn ] ) require ; patient negative microscopically axillary positive sentinel node ( pN1mi : micrometastasis none &gt; 2.0 mm ) require axillary therapy ; positive sentinel node must either axillary dissection radiation axillary node For International Breast Cancer Study Groups ( IBCSG ) center , patient must complete baseline Quality Life ( QL ) Forms prior randomization ; exception cognitive physical impairment interfere QL assessment inability read language available IBCSG QL form ; nonIBCSG center , extent participation QL study determine activation trial cooperative group Written inform consent must sign dated patient investigator prior randomization Patients must accessible followup Patients must inform agree data tissue material transfer handling , accordance national data protection guideline Patients postmenopausal ( i.e. , estradiol [ E2 ] level premenopausal range ) surgery chemotherapy , whichever later Patients distant metastatic disease Patients locally advance inoperable breast cancer include inflammatory breast cancer supraclavicular node involvement enlarge internal mammary node ( unless pathologically negative ) eligible ; patient involve internal mammary node detect sentinel node biopsy enlarge eligible Patients positive final margin ( refer DCIS invasive cancer , lobular breast carcinoma situ [ LCIS ] ) , except note ; DCIS margin permit complete mastectomy perform Patients clinically detectable residual axillary disease Patients history prior ipsilateral contralateral invasive breast cancer ; patient synchronous bilateral invasive breast cancer ( diagnose histologically within 2 month ) eligible bilateral disease meet eligibility criterion Patients previous concomitant invasive malignancy eligible ; exception patient follow ( follow ) malignancy ( previous concomitant ) eligible adequately treat : Basal squamous cell carcinoma skin In situ nonbreast carcinoma without invasion Contra ipsilateral situ breast carcinoma Nonbreast invasive malignancy diagnose least 5 year ago without recurrence : Stage I papillary thyroid cancer Stage Ia carcinoma cervix Stage Ia b endometrioid endometrial cancer Borderline stage I ovarian cancer Patients nonmalignant systemic disease ( cardiovascular , renal , hepatic , lung , etc . ) would prevent prolonged followup ; patient previous thrombosis ( e.g. , deep vein thrombosis [ DVT ] ) and/or embolism include medically suitable Patients bilateral oophorectomy ovarian irradiation ; patient recommend undergo oophorectomy within 5 year ( e.g. , breast cancer susceptibility gene [ BRCA ] 1/2 gene carrier ) therefore randomization treatment arm without OFS inappropriate Patients history noncompliance medical regimen patient consider potentially unreliable Patients pregnant lactating time randomization desire pregnancy within 5 year ; patient plan use additional hormonal therapy apart randomize treatment next five year include type hormonal contraception ; pregnancy test recommended woman childbearing potential sexually active use reliable contraceptive method Patients receive endocrine therapy ( include neoadjuvant adjuvant ) 8 month breast cancer diagnosis ; patient receive endocrine therapy randomization ( receive less 8 month ) may continue therapy protocolspecified tamoxifen/exemestane initiate Patients take tamoxifen selective estrogen receptor modulator ( SERM ) ( e.g . Raloxifene ) hormone replacement therapy ( HRT ) within one year prior breast cancer diagnosis ; prior oral contraceptive allow Patients receive GnRH analogue part breast cancer treatment prior randomization Patients psychiatric , addictive , disorder would prevent compliance protocol requirement</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>tamoxifen</keyword>
	<keyword>ovarian function suppression + tamoxifen</keyword>
	<keyword>ovarian function suppression + exemestane</keyword>
</DOC>